Weight gain in CML patients after imatinib therapy
| Months after imatinib therapy . | N . | Median weight gain (kg) . | % weight gain . | P . | No. of patients with weight gain . |
|---|---|---|---|---|---|
| 6 | 48 | 3.4 (−6.0, 11.0) | 4.8 (−5.3, 14.2) | < .0001 | 37 (77%) |
| 12 | 45 | 4.1 (−3.1, 17.9) | 5.3 (−4.2, 22.9) | < .0001 | 38 (84%) |
| 18 | 43 | 4.7 (−3.4, 17.9) | 6.3 (−4.8, 23.0) | < .0001 | 36 (84%) |
| 24 | 35 | 5.2 (−8.4, 21.7) | 6.2 (−12.0, 27.1) | < .0001 | 30 (83%) |
| Months after imatinib therapy . | N . | Median weight gain (kg) . | % weight gain . | P . | No. of patients with weight gain . |
|---|---|---|---|---|---|
| 6 | 48 | 3.4 (−6.0, 11.0) | 4.8 (−5.3, 14.2) | < .0001 | 37 (77%) |
| 12 | 45 | 4.1 (−3.1, 17.9) | 5.3 (−4.2, 22.9) | < .0001 | 38 (84%) |
| 18 | 43 | 4.7 (−3.4, 17.9) | 6.3 (−4.8, 23.0) | < .0001 | 36 (84%) |
| 24 | 35 | 5.2 (−8.4, 21.7) | 6.2 (−12.0, 27.1) | < .0001 | 30 (83%) |
CML indicates chronic myeloid leukemia.